Profile data is unavailable for this security.
About the company
Hunan Fangsheng Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company primarily operates its businesses through two segments. The Pharmaceutical Manufacturing Business segment mainly provides cardiovascular and cerebrovascular drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs and anti-infective drugs. The Company's main products include Xuesetong dispersible tablets, Xuesetong tablets, Garcinia bone-strengthening tablets, Dieda Huoxue capsules, Lysine Vitamin B12 granules, Cefuroxime tablets, Jinying capsules, Pudilan anti-inflammatory tablets, Xiaoer Jingxing cough granules, Ezetimibe tablets, Xuanqi bone-strengthening tablets, Qiangli Loquat Paste (honey-refined), Qiangli Loquat Dew and others. The Others segment is mainly engaged in other businesses such as medical services, pharmaceutical commerce and drug sales.
- Revenue in CNY (TTM)1.76bn
- Net income in CNY272.96m
- Incorporated1997
- Employees1.69k
- LocationHunan Fangsheng Pharmaceutical Co LtdNo.19 Lutian Road, Lugu, HexiCHANGSHA 410205ChinaCHN
- Phone+86 73 188997135
- Fax+86 73 188908647
- Websitehttp://www.fangsheng.com.cn
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shouyao Holdings Co Ltd | 4.03m | -209.50m | 4.98bn | 185.00 | -- | 5.79 | -- | 1,236.51 | -1.41 | -1.41 | 0.0271 | 5.79 | 0.0038 | 0.1616 | 5.03 | 21,779.19 | -19.57 | -37.24 | -21.64 | -42.63 | 95.48 | 96.03 | -5,199.60 | -2,251.77 | 7.06 | -- | 0.0087 | -- | 186.18 | -23.51 | -6.76 | -- | 34.59 | -- |
| Sinotherapeutics Inc | 449.12m | 109.57m | 5.00bn | 260.00 | 45.68 | 4.05 | -- | 11.14 | 0.2417 | 0.2417 | 0.9907 | 2.73 | 0.3228 | 2.50 | 5.20 | 1,727,366.00 | 7.88 | -- | 8.54 | -- | 53.66 | -- | 24.40 | -- | 7.95 | -- | 0.00002 | -- | 21.13 | -- | -34.29 | -- | -- | -- |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 1.82bn | 112.88m | 5.17bn | 2.47k | 45.76 | 4.47 | -- | 2.84 | 0.2821 | 0.2821 | 4.55 | 2.89 | 0.6323 | 2.49 | 3.22 | 737,841.70 | 4.09 | 5.81 | 6.24 | 9.78 | 53.91 | 58.01 | 6.48 | 7.03 | 0.7573 | 12.48 | 0.5316 | 21.74 | 25.75 | 14.13 | 24.29 | 1.16 | 46.37 | -- |
| Shanghai Haixin Group Co Ltd | 841.27m | 178.76m | 5.40bn | 760.00 | 40.32 | 1.65 | -- | 6.42 | 0.1481 | 0.1481 | 0.697 | 3.62 | 0.1607 | 5.09 | 6.89 | 1,106,933.00 | 4.06 | 2.68 | 4.52 | 3.06 | 52.44 | 44.55 | 25.25 | 11.17 | 3.01 | -- | 0.0077 | 36.10 | -17.88 | 1.48 | 1.20 | 4.19 | -10.27 | 13.18 |
| Hunan Fangsheng Pharmaceutical Co Ltd | 1.76bn | 272.96m | 5.42bn | 1.69k | 19.78 | 3.40 | -- | 3.08 | 0.6244 | 0.6244 | 4.05 | 3.63 | 0.5513 | 1.43 | 6.70 | 1,044,835.00 | 8.34 | 5.39 | 14.83 | 9.37 | 69.28 | 66.91 | 15.12 | 8.95 | 0.4736 | -- | 0.3161 | 46.47 | -9.12 | 9.15 | -34.64 | 20.68 | 23.91 | 4.75 |
| Guizhou Sanli Pharmaceutical Co Ltd | 2.11bn | 328.87m | 5.79bn | 2.28k | 18.13 | 3.62 | -- | 2.74 | 0.7798 | 0.7798 | 5.05 | 3.91 | 0.8372 | 2.90 | 4.48 | 925,761.20 | 13.32 | 12.39 | 19.88 | 16.72 | 69.37 | 70.45 | 15.91 | 16.31 | 1.62 | -- | 0.2373 | 25.70 | 36.10 | 17.75 | 45.42 | 21.51 | 127.48 | -- |
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 34.07m | 8.01% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 21.55m | 5.07% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 14.27m | 3.36% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 7.17m | 1.69% |
| Great Wall Fund Management Co., Ltd.as of 30 Jun 2024 | 6.55m | 1.54% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 4.65m | 1.09% |
| Changan Fund Management Co. Ltd.as of 30 Jun 2024 | 4.31m | 1.01% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 3.44m | 0.81% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 3.43m | 0.81% |
| Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2024 | 2.90m | 0.68% |
